And once again my itchy nose had put this share on my watch because of its high earnings growth and 3% dividend yield.
" You have beautiful hair "
Cosmo's shares shot up on Wednesday after the company said it had presented groundbreaking study data.
03.12.2025 09:47
Cosmo shares shot up 23 percent on Wednesday and are now trading at over 80 francs. The day before, they had closed at 65.50 francs. The share price has risen by just 2.8 percent since January.
The pharmaceutical company had presented new study data on the hair loss drug Clascoterone, which delivered "groundbreaking results". The communiqué refers to a "potential first major therapeutic breakthrough" in the treatment of hair loss in more than three decades. The active ingredient is the first of its kind to target the biological cause of male hair loss.
According to the press release, Clascoterone has led to a relative improvement in hair count of 539 percent and 168 percent compared to the placebo drug. Cosmo now intends to complete the required twelve-month safety follow-up by spring 2026. Following this, it plans to immediately submit parallel applications for approval in the USA and Europe.
There are currently only buy recommendations for the share. The average target price of CHF 98 is well above the current share price. The analysts' recommendations have all been adjusted since July of this year and are therefore up to date.
Nicolas Pauillac from Kepler Cheuvreux is one of the covering experts. He raised the target price in July, from CHF 100 to CHF 101. He bases his buy recommendation in particular on an improvement in market sentiment and the forthcoming results of phase III of Breezula, which he sees as the most important short-term catalyst.
Investors need to be patient
Such "groundbreaking results" as today's are also urgently needed. Equities have not exactly had rosy times: in the last ten years, they have lost more than 60 percent, while the overall markets have risen by roughly the same percentage.
Above all, Cosmo investors need patience and must hope for research successes. If this happens, billions in sales are waiting for the Group in this huge market. According to Cosmo, 1.2 to 2 billion men worldwide suffer from hair loss.
However, the management in Lugano and Dublin still seems confident. By 2030, Cosmo wants to grow by 39 percent annually and achieve a turnover of 480 million euros and an EBITDA of 195 million euros. Almost half of this is to come from new products, while the remaining growth is to be largely driven by the existing core business.
The pharmaceutical group had also raised its forecast for the year as a whole. EBITDA is not expected to be between 1 and 3 million euros as previously, but between 5.5 and 7.5 million euros. Total turnover is still expected to be between 102 and 107 million euros.
(cash)
